We tested the hypothesis that salt and fluid retention in heart-transplant recipients (HTRs) is caused by a failure to reflexively suppress the renin-angiotensin-aldosterone system (RAAS). BACKGROUND It is known that extracellular fluid volume is expanded (12% to 15%) in HTRs who develop hypertension.
Hypertension is a frequent complication of heart transplantation with as many as 80% of heart-transplant recipients (HTRs) requiring treatment for this disorder (1) (2) (3) . The underlying pathogenic mechanisms remain unclear. Posttransplant hypertension is unrelated to pre-existing hypertension and refractory to standard antihypertensive pharmacologic therapy in some HTRs (1) (2) (3) 
. Mechanisms responsible for de novo hypertension in HTRs include
See page 433 vascular stiffness and endothelial dysfunction, which appear to persist indefinitely after transplantation (3) , and cyclosporine-mediated side effects, including sympathoexcitation (4) and nephrotoxicity (5) . However, hypertension in HTRs is more severe than in other transplant populations and reductions in cyclosporine dose, serum concentration, and duration of therapy fail to reduce the incidence of hypertension (1) (2) (3) . Moreover, HTRs who never receive cyclosporine also have a high incidence of hypertension (6) . Against this background, it is appropriate to conclude that de novo hypertension in HTRs extends beyond cyclosporine-related mechanisms.
Our laboratory has focused upon the putative role of extracellular fluid volume expansion in transplant hypertension. Extracellular fluid volume expansion (ϳ12%) is well documented in HTRs who become hypertensive (7) (8) (9) (10) . Theoretically, a fluid volume increase of only 3% to 4% can result in sustained hypertension (11) . In a previous study, we acutely infused isotonic saline and determined that blood pressure in HTRs is highly salt sensitive (8) . We also observed that HTRs have blunted diuretic and natriuretic responses to fluid volume expansion that may be mediated by a failure to reflexly suppress the renin-angiotensinaldosterone system (RAAS), secondary to cardiac denervation (8) .
The purpose of this study was to determine whether salt and water retention in HTRs are caused by an inability to suppress the RAAS when these patients become hypervolemic. We hypothesized that pharmacologic suppression of the RAAS would normalize renal salt and water handling in HTRs. We further speculated that improved salt and water elimination would lower systemic blood pressure. Using a crossover design, we measured blood pressure, renal, and endocrine responses to acute extracellular fluid volume expansion in HTRs under standardized conditions both before and after angiotensin-converting enzyme inhibition (ACEi) with captopril (Capoten). Responses in HTRs before and after ACEi were compared with responses in liver-transplant recipients (LTRs), who served as both cyclosporine and cardiac-innervated control subjects.
METHODS

Subjects.
Eight male HTRs (57 Ϯ 6 years of age) were entered into the study 22 Ϯ 4 months (group mean) after transplantation. The HTRs were clinically stable and free from significant rejection, infection, or other major illness and all received immunosuppressive therapy with cyclosporine, prednisone, and azathioprine. The HTRs were receiving maintenance prednisone of 5 to 10 mg/day at the time of the study, and no HTRs required enhanced glucocorticoid doses within six months of the study. All HTRs had biatrial anastomosis at transplantation. The HTRs underwent endomyocardial biopsy within two months of the study, and there was no evidence of rejection at the time of biopsy in any of the subjects. Whole-blood cyclosporine trough levels, calculated as an average of four determinations over six months before the study were 225 Ϯ 18 ng/ml (group mean). None of the transplant recipients were hypertensive before transplantation, but all required antihypertensive agents after transplantation. No HTRs had evidence of cardiac allograft vascular disease. Six male LTRs (52 Ϯ 2 years of age) immunosuppressed with cyclosporine were also recruited to participate in the study as a cyclosporine and cardiac-innervated control group. Whole-blood cyclosporine trough levels, calculated as an average of four determinations over six months before the study, were similar in the heart (225 Ϯ 18 ng/ml) and liver (241 Ϯ 31 ng/ml) transplant recipients. Study design. This study was a crossover design. Blood pressure, renal, and endocrine responses to acute extracellular fluid volume expansion were measured in the same cohort of HTRs and LTRs under two conditions: study period 1-after discontinuation of all diuretics and antihypertensive agents; and study period 2, after a 14-day regimen of ACEi consisting of a target dose of 225 mg/24 h of captopril. The two study periods were separated by 16 Ϯ 5 weeks (mean Ϯ SD). The protocol was approved by the Institutional Review Board for the protection of human subjects at the University of Florida and all subjects provided written informed consent to participate in the study. Protocol without captopril. Diuretics and all antihypertensive agents were discontinued 10 days before the study. Antihypertensive agents included calcium channel blockers (eight of eight HTRs), diuretics (four of eight HTRs), and ACEi (two of eight HTRs). No alpha-or beta-blockers or other cardiac medications were used by the transplant recipients. Subjects were admitted to the clinical research center (CRC). The first three days in the CRC consisted of an equilibration to a diet that consisted of sufficient calories to maintain current weight and provided 87 mEq/24 h of Na ϩ and 80 mEq/24 h of K ϩ . Water intake was standardized to 1,000 ml on day 3 but provided ad libitum on all other days of the study. Consumption of alcohol, caffeine, and tobacco products was not allowed.
Subjects were awakened each morning at 7:00 AM and, while still supine, blood pressure was recorded in triplicate using an automated system (Datascope Corp., Paramus, New Jersey). Blood samples were drawn from an indwelling venous catheter for analysis of plasma concentrations of arginine vasopressin (AVP), angiotensin II (ANG II), aldosterone (ALDO), and atrial natriuretic peptide (ANP). A 24-h urine collection was started each morning at 7:00 AM. All subjects had Ϯ15% of Na ϩ balance before the saline infusion studies conducted on day 4.
On day 4, the blood pressure, renal, and endocrine responses to saline infusion were determined. At 7 AM the subjects were awakened, blood samples were obtained, and the subjects then stood and voided. Creatinine clearance was determined from the 24-h urine sample. After 1 h, the subject again voided and returned to the supine posture and remained supine until completion of the infusion. Isotonic saline (0.154 mol/l) was infused at 8 ml/kg/h for 4 h. Blood pressure, heart rate, and blood samples were drawn before the infusion and at 30, 60, 120, and 240 min during the infusion. Urine was collected at 2 and 4 h during the infusion. After completion of the infusion, an 8-h urine collection was started. Thereafter, 12-h collections were performed until the completion of the study. The 7-AM sample collection regimen described earlier was repeated on days 5 and 6. The protocol provided 48 h of observation for blood pressure, renal salt and water elimination, and hormone levels after onset of the volume expansion stimulus. After the 48-h period of observation, the diuretic and antihypertensive agents subjects received before study entry were restarted, and the subjects were discharged from the CRC. Protocol with captopril. After approximately four months (group mean 16 Ϯ 5 weeks), the same cohort of heart (n ϭ 8) and LTRs (n ϭ 6) again discontinued all diuretic and
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Braith et al. February 5, 2003:426-32 Fluid Homeostasis in HTRs antihypertensive agents. Subjects were then progressed through a three-week home-based regimen of ACEi that consisted of a target dose of 225 mg/day of captopril. After 14 days at the target ACEi dose, subjects were admitted a second time to the CRC. The equilibration protocol and volume expansion experiments described above were repeated for each subject. After a 48-h period of observation and data collection, diuretic and antihypertensive agents were restarted, and the subjects were discharged from the CRC. Blood sample collection. Blood samples for AVP, ANG II, ALDO, and ANP were drawn into vacutainers containing ethylenediaminetetraacetic acid. Plasma was separated by centrifugation at 3,500 g at 4°C for 20 min and the samples were frozen at Ϫ80°C until the assays were performed. Neurohormone analyses. The plasma volume and neurohormone assays used in the present study have been used reliably in our laboratory for numerous experiments with human subjects (8 -10,12,13) . Plasma AVP was measured by radioimmunoassay as previously described (14) . Plasma ANG II and ALDO levels were determined by radioimmunoassay as previously described by Braith et al. (12) . Atrial natriuretic peptide was extracted from plasma using a modification of a technique described by Braith et al. (13) . Radioimmunoassay was performed with a kit from Peninsula Laboratories (Belmont, California) using ANP antiserum that has 0% cross-reactivity with human brain natriuretic peptide and C-type natriuretic peptide. Electrolyte and creatinine analyses. Sodium and potassium concentrations in urine and plasma were measured using a Nova 1 electrolyte analyzer (Nova Biomedical, Waltham, Massachusetts 
RESULTS
Clinical status. There were no changes in clinical status for any HTR or LTR between the two admissions to the CRC. There were no significant changes in body weight between the protocol without captopril (94.3 Ϯ 6 kg) and the protocol with captopril (93.1 Ϯ 7 kg). The immunosuppression regimen was not changed for any subject during the study. Cardiac function. The hemodynamic and left ventricular function data in HTRs are presented in Table 1 . The mean cardiac index was 2.80 Ϯ 0.53 l/min/m 2 , which falls within the lower one third of the normal range of 2.4 to 4.2 l/min/m 2 (15) . Right atrial pressure for the group was slightly elevated at 6.1 Ϯ 1.0 mm Hg, which was 22% greater than the accepted maximal right atrial mean pressure of 5 mm Hg, whereas the mean occluded pulmonary artery pressure of 10. CI ϭ cardiac index; EF ϭ ejection fraction; HTRs ϭ heart transplant recipients; IV Septum ϭ ventricular septal thickness; PCW ϭ pulmonary capillary wedge pressure; PW ϭ posterior ventricular wall thickness; RAP ϭ right atrial pressure. Urine volume during the 4-h saline infusion increased similarly (p Ն 0.05) in HTRs and LTRs both before and after ACEi (Fig. 2) . However, urine volume at 12 and 24 h after the infusion was significantly (p Յ 0.05) diminished in HTRs without ACEi when compared with HTRs with ACEi and LTRs both with and without ACEi. Urine volume in liver patients after the saline infusion was not different (p Ն 0.05) before and after ACEi. The net urine output over 48 h in LTRs was 82 Ϯ 15 ml/kg with ACEi and 80 Ϯ 17 ml/kg without ACEi. The net urine output over 48 h in HTRs was significantly greater (p Յ 0.05) with ACEi (78 Ϯ 11 ml/kg) than without ACEi (64 Ϯ 14 ml/kg).
Urinary salt elimination in LTRs during the 4-h saline infusion was the same with and without ACEi (Fig. 2) . In HTRs before ACEi, however, natriuresis was significantly less (p Յ 0.05) during the 4-h saline infusion and remained significantly diminished (p Յ 0.05) until 36 h after the saline infusion when compared with HTRs with ACEi and LTRs with or without ACEi. A delayed natriuretic re- (Fig. 3) . The ANG II and ALDO levels returned slowly toward baseline over the next 48 h. In stark contrast, saline infusion in HTRs both before and after ACEi did not elicit reflex suppression of ANG II and ALDO at any point during the 4-h infusion or 48-h observation period. In LTRs receiving ACEi, saline infusion suppressed ANG II and ALDO to levels that were below the reliable detection limitation of our assay. The changes in baseline supine resting AVP levels in both HTRs and liver patients after ACEi did not reach statistical significance (p Ն 0.05), when compared with values before ACEi ( Table 2 ). In LTRs both before and after ACEi, volume expansion elicited reflex suppression of plasma AVP to levels that were significantly lower than baseline values (Fig. 4) . Conversely, in HTRs both before and after ACEi, AVP values were not suppressed below baseline during the infusion. Rather, there was a slight but significant paradoxical rise in AVP during saline infusion that is likely related to an inability to reflexly suppress AVP and also to an increase in plasma osmolality.
Baseline ANP levels were elevated (p Յ 0.05) in HTRs compared with LTRs both before and after ACEi ( Table 2 ). The changes in baseline supine resting ANP levels in both HTRs and LTRs after ACEi did not reach statistical significance (p Ն 0.05), when compared with values before ACEi. Volume expansion elicited comparable increases in ANP in both groups of subjects before and after ACEi (Fig.  4) . Cardiac responses. Volume expansion with isotonic saline elicited a significant baroreflex-mediated decrease in supine heart rate in the LTRs both before (63 Ϯ 5 to 58 Ϯ 4 beats/min) and after ACEi (62 Ϯ 4 to 57 Ϯ 3 beats/min).
However, heart rate remained constant throughout the 48-h postinfusion observation period in HTRs both with (80 Ϯ 7 to 80 Ϯ 9 beats/min) and without ACEi (79 Ϯ 7 to 80 Ϯ 8 beats/min).
DISCUSSION
Principal findings. There were two main findings of this study: 1) Short-term pharmacologic suppression of the RAAS with high-dose captopril (225 mg/day) eliminated avid salt and fluid retention in HTRs. Before ACEi, HTRs demonstrated blunted and abnormally abbreviated diuresis (Table 1) . Thus, with normal systolic function, the avid salt and water retention that we observed in HTRs before ACEi cannot be attributed to differences in cardiac output. However, our hemodynamic and fluid homeostasis measurements were not simultaneous. Rather, the hemodynamic assessments in HTRs were performed during the interval (16 Ϯ 5 weeks; group mean Ϯ SD) between the first (without ACEi) and second (with ACEi) fluid balance measurements, and therefore somewhat limit the generalization of cardiac hemodynamic data to the physiologic state of the patient at the specific times that fluid volume was studied.
Cyclosporine and renal function. Most reports of fluid retention in organ-transplant recipients have emphasized cyclosporine-induced nephrotoxicity (1-6). The adverse effects of cyclosporine include an increase in renal vascular resistance and a concomitant decrease in the glomerular filtration rate and renal blood flow; these effects are clearly associated with fluid retention. In the present study, we relied on the semiquantitative estimate of glomerular filtration rate using endogenous creatinine clearance. Although this technique may not be sufficiently sensitive to detect small differences in filtration in HTRs before and after ACEi, our data indicate that the glomerular filtration rate was the same in our cohort of HTRs before and after high-dose ACEi. Our finding of normal salt and fluid elimination in HTRs after ACEi, despite unchanged cyclosporine dose and cyclosporine trough levels, clearly shows that cyclosporine side effects alone are not an adequate explanation for the avid salt and fluid retention observed in HTRs. Moreover, defects in blood pressure and fluid homeostasis were not observed in our control group of LTRs despite the fact that they were receiving doses of cyclosporine comparable to the HTRs. Rather, our findings indicate that the moderate fluid retention that we have described in HTRs is derived from the combination of a deafferented heart (ablation of cardiac volume receptors and failure to reflexively suppress the RAAS during hypervolemia) and the use of cyclosporine, which further attenuates renal salt and water elimination. Clinical relevance. Hypertension is a frequent complication of heart transplantation attributed to cyclosporineinduced nephrotoxicity and endothelial dysfunction (1) (2) (3) (4) . However, viewing the transplanted heart as a deafferented volume-sensing organ provides an alternative explanation for the incidence and severity of hypertension in HTR. Extracellular fluid volume expansion (12% to 15%) is well documented in clinically stable HTRs who become hypertensive (7-10). Failure to reflexively suppress the RAAS 
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